LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...